Department of Economics and Business Economics

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. / Dalsgaard, Søren; ICASA consensus group.

In: European Addiction Research, Vol. 24, No. 1, 2018, p. 43-51.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{ee2fbd7c30d84a4d8d7f1648433121c7,
title = "International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder",
abstract = "Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.",
author = "Crunelle, {Cleo L} and {van den Brink}, Wim and Franz Moggi and Maija Konstenius and Johan Franck and Levin, {Frances R} and {van de Glind}, Geurt and Zsolt Demetrovics and Corn{\'e} Coetzee and Mathias Luderer and Arnt Schellekens and Frieda Matthys and S{\o}ren Dalsgaard and ICASA consensus group",
note = "{\circledC} 2018 S. Karger AG, Basel.",
year = "2018",
doi = "10.1159/000487767",
language = "English",
volume = "24",
pages = "43--51",
journal = "European Addiction Research",
issn = "1022-6877",
publisher = "S. Karger AG",
number = "1",

}

RIS

TY - JOUR

T1 - International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder

AU - Crunelle, Cleo L

AU - van den Brink, Wim

AU - Moggi, Franz

AU - Konstenius, Maija

AU - Franck, Johan

AU - Levin, Frances R

AU - van de Glind, Geurt

AU - Demetrovics, Zsolt

AU - Coetzee, Corné

AU - Luderer, Mathias

AU - Schellekens, Arnt

AU - Matthys, Frieda

AU - Dalsgaard, Søren

AU - ICASA consensus group

N1 - © 2018 S. Karger AG, Basel.

PY - 2018

Y1 - 2018

N2 - Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.

AB - Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.

U2 - 10.1159/000487767

DO - 10.1159/000487767

M3 - Journal article

C2 - 29510390

VL - 24

SP - 43

EP - 51

JO - European Addiction Research

JF - European Addiction Research

SN - 1022-6877

IS - 1

ER -